Target Advancement Program | Parkinson's Disease Information - 0 views
-
MiamiOH OARS on 18 Feb 16The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.
-
MiamiOH OARS on 18 Feb 16The Michael J. Fox Foundation believes that a major hurdle in the development of promising treatments for Parkinson's disease is the need for well-validated targets linked to the disease process. By promoting critical target validation studies within academic and industry laboratories, MJFF investments can help de-risk subsequent drug development and ultimately accelerate the creation of innovative therapies for Parkinson's patients. Part of our Edmond J. Safra Core Programs for PD Research, the Target Advancement program seeks to build robust evidence to rationalize biological pathways and targets for further translation into new Parkinson's treatments.